Australia's most trusted
source of pharma news
Saturday, 10 May 2025
Posted 6 May 2025 AM
New Zealand's Pharmac is considering some big name drugs in upcoming meetings of advisory committees.
On the May agenda for the Pharmacology and Therapeutics Advisory Committee (PTAC) is AstraZeneca's PD-L1 inhibitor Imfinzi, in combination with etoposide and either carboplatin or cisplatin, to treat people with extensive-stage small cell lung cancer (ES-SCLC).
Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.